Researchers discovered that the aging gastrointestinal tract produces specific molecules that blunt the activity of a key gut-brain neuronal pathway, leading to age-related cognitive decline. Stimulating specific gut sensory neurons and targeting the vagus nerve can restore youthful cognitive function in old mice, suggesting that brain...
Researchers at Arc Institute and Stanford University found that ketone body β-hydroxybutyrate strengthens CAR T cell fitness and antitumor activity. BHB supplementation improves CAR T cell expansion and tumor killing in mice, mirroring the effects of a ketogenic diet.
The AI model can accurately identify disease-causing mutations in human genes and is capable of designing new genomes that are as long as the genomes of simple bacteria. Evo 2 has been trained on over 100,000 species across the entire tree of life and can process genetic sequences of up to 1 million nucleotides at once.
Researchers developed a systematic framework for matching nutrients to genetic diseases, identifying vitamins B2 and B3 as key players in treating various conditions. The study's findings also revealed a new vitamin-disease interaction involving the NAXD gene and vitamin B3.
Researchers developed MULTI-evolve, a framework for efficient protein evolution that applies machine learning models to predict beneficial mutations and their combinations. The approach identified function-enhancing mutations and tested their pairwise combinations, demonstrating improved efficiency in protein engineering.
Research reveals that people living at high altitudes have better glucose control due to an increased ability of red blood cells to take up and metabolize glucose. Studies in mice show that this occurs when RBCs are reprogrammed by hypoxic conditions, allowing them to adapt to low oxygen levels and aid the body's oxygen delivery.
The study reveals that orphan non-coding RNAs (oncRNAs) exist across all major cancer types and can be used as digital molecular barcodes to capture cancer cell identity. The research also identifies oncRNAs that drive cancer progression, with some showing promise as biomarkers for monitoring patients.
Researchers from Arc Institute, UCSF, and Fred Hutchinson Cancer Center identified PTGES3 as a key regulator of the androgen receptor in prostate cancer. The study found that PTGES3 contributes to tumor growth and suggests it could be a promising new target for treating aggressive prostate cancers.
Researchers create enhanced T cells with improved survival in cancer models by simultaneously modifying multiple genes using CRISPRoff and CRISPRon. The approach overcomes toxicity issues associated with traditional gene editing methods, enabling high cell survival rates and potential for treating various diseases.
Researchers developed bridge recombinase technology, allowing for large genomic region manipulation and potential applications in genetic therapies. The system enables efficient insertion, excision, and inversion of genomic sequences with high specificity.
Researchers have developed an immunotherapy drug STF-1623 that safely prevents cancer cells from hiding from the immune system's first responders. The drug works by inhibiting ENPP1 proteins that destroy cGAMP, allowing it to trigger a broader immune response and suppress tumor growth.
A study by Arc Institute and Stanford University scientists reveals that the target site of a popular STING inhibitor lacks a pocket found in mouse STING, making it challenging to develop effective human treatments. The research proposes targeting STING by preventing oligomerization, a key checkpoint prior to activation.
The Arc Institute has launched its inaugural Virtual Cell Challenge, a public competition using AI to solve one of biology's biggest challenges. Competitors will train models on gene expression data from over half a billion cells and predict changes in gene activity when individual genes are silenced.
The Arc Virtual Cell Atlas has partnered with 10x Genomics and Ultima Genomics to generate high-quality perturbational single-cell data at scale. Leveraging 10x's Chromium Flex technology and Ultima's UG 100 sequencing system, researchers will create increasingly powerful AI models in biology.
The Arc Institute is collaborating with NVIDIA to develop powerful computational models and tools for biomedical research. The partnership aims to advance the capabilities of the global biomedical research community through the use of generative AI.
Researchers at the Arc Institute have discovered a novel bispecific guide RNA, the bridge recombinase mechanism, which enables precise and powerful tool to recombine and rearrange DNA in a programmable way. The system can insert any desirable genetic cargo into any genomic location with high efficiency and specificity.
Researchers at UCSF and Arc Institute have discovered a cellular uptake pathway for larger drug molecules composed of linked subunits. This knowledge can be harnessed to create new drugs that are efficiently taken up by target cells, overcoming a fundamental challenge in drug discovery.